Thromboxane Formation Assay to Identify High On-Treatment Platelet Reactivity to Aspirin

被引:6
|
作者
Mohring, Annemarie [1 ]
Piayda, Kerstin [1 ]
Dannenberg, Lisa [1 ]
Zako, Saif [1 ]
Schneider, Theresa [1 ]
Bartkowski, Kirsten [2 ]
Levkau, Bodo [3 ]
Zeus, Tobias [1 ]
Kelm, Malte [1 ]
Hohlfeld, Thomas [2 ]
Polzin, Amin [1 ]
机构
[1] Heinrich Heine Univ, Med Ctr Dusseldorf, Div Cardiol Pulmonol & Vasc Med, Dusseldorf, Germany
[2] Heinrich Heine Univ, Inst Pharmacol & Clin Pharmacol, Dusseldorf, Germany
[3] Univ Duisburg Essen, Univ Hosp Essen, Inst Pathophysiol, West German Heart & Vasc Ctr, Essen, Germany
关键词
Aspirin; Platelet activation; Platelet inhibition; High on-treatment reactivity; Thromboxane; DIPYRONE METAMIZOLE; CORONARY; INHIBITION;
D O I
10.1159/000477303
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Platelet inhibition by aspirin is indispensable in the secondary prevention of cardiovascular events. Nevertheless, impaired aspirin antiplatelet effects (high on-treatment platelet reactivity [HTPR]) are frequent. This is associated with an enhanced risk of cardiovascular events. The current gold standard to evaluate platelet hyper-reactivity despite aspirin intake is the light-transmittance aggregometry (LTA). However, pharmacologically, the most specific test is the measurement of arachidonic acid (AA)-induced thromboxane (TX) B2 formation. Currently, the optimal cut-off to define HTPR to aspirin by inhibition of TX formation is not known. Therefore, in this pilot study, we aimed to calculate a TX formation cut-off value to detect HTPR defined by the current gold standard LTA. We measured platelet function in 2,507 samples. AA-induced TX formation by ELISA and AA-induced LTA were used to measure aspirin antiplatelet effects. TX formation correlated nonlinearly with the maximum of aggregation in the AA-induced LTA (Spearman's rho R = 0.7396; 95% CI 0.7208-0.7573, p < 0.0001). Receiver operating characteristic analysis and Youden's J statistics revealed 209.8 ng/mL as the optimal cut-off value to detect HTPR to aspirin with the TX ELISA (area under the curve: 0.92, p < 0.0001, sensitivity of 82.7%, specificity of 90.3%). In summary, TX formation ELISA is reliable in detecting HTPR to aspirin. The calculated cut-off level needs to be tested in trials with clinical end points. (C) 2017 S. Karger AG, Basel
引用
收藏
页码:127 / 130
页数:4
相关论文
共 50 条
  • [31] The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists'-inducible platelet reactivity
    Gremmel, Thomas
    Kopp, Christoph W.
    Seidinger, Daniela
    Giurgea, Georgiana-Aura
    Koppensteiner, Renate
    Steiner, Sabine
    Panzer, Simon
    ATHEROSCLEROSIS, 2009, 207 (02) : 608 - 613
  • [32] High on-treatment platelet reactivity-an OPTIMAl solution, or a better solution?
    Hills, Robert K.
    BRITISH JOURNAL OF HAEMATOLOGY, 2022, 196 (02) : 272 - 273
  • [33] On-treatment platelet reactivity: State of the art and perspectives
    Marcucci, Rossella
    Grifoni, Elisa
    Giusti, Betti
    VASCULAR PHARMACOLOGY, 2016, 77 : 8 - 18
  • [34] Variability of on-treatment platelet reactivity in patients on clopidogrel
    Freynhofer, Matthias K.
    Bruno, Veronika
    Brozovic, Ivan
    Jarai, Rudolf
    Vogel, Birgit
    Farhan, Serdar
    Huebl, Wolfgang
    Willheim, Martin
    Wojta, Johann
    Huber, Kurt
    PLATELETS, 2014, 25 (05) : 328 - 336
  • [36] High on-treatment platelet reactivity in peripheral arterial disease: A systematic review
    Goncalves, Lauren N.
    van Velze, Veerle
    Klok, Frederikus A.
    Gal, Pim
    Vos, Rimke C.
    Hamming, Jaap F.
    van der Bogt, Koen E. A.
    VASCULAR, 2024, 32 (06) : 1177 - 1190
  • [37] High on-treatment platelet reactivity to both aspirin and clopidogrel is associated with the highest risk of adverse events following percutaneous coronary intervention
    Breet, Nicoline J.
    van Werkum, Jochem W.
    Bouman, Heleen J.
    Kelder, Johannes C.
    Harmsze, Ankie M.
    Hackeng, Christian M.
    ten Berg, Jurrien M.
    HEART, 2011, 97 (12) : 983 - 990
  • [38] High triglyceride is an independent predictor of high on-treatment platelet reactivity in ischemic stroke patients
    Chen, Haoxuan
    Zhan, Yibo
    Lou, Zhenzhen
    Mao, Hui
    Zhang, Changlin
    Li, Xiaojun
    Chen, Guixian
    Ouyang, Huiying
    Huang, Zhiping
    Wen, Longlong
    Xu, Haoyou
    Zheng, Zequan
    Zhao, Yuanqi
    Zhao, Min
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2022, 31 (06):
  • [39] The formation of monocyte-platelet aggregates is independent of on-treatment residual agonists-inducible platelet reactivity
    Gremmel, T.
    Kopp, C. W.
    Seidinger, D.
    Koppensteiner, R.
    Steiner, S.
    Panzer, S.
    EUROPEAN HEART JOURNAL, 2009, 30 : 196 - 197
  • [40] HIGH ON-TREATMENT PLATELET REACTIVITY IS A PREDICTOR OF RESTENOSIS IN PATIENTS WITH CORONARY STENT IMPLANTATION
    Ueda, Hironori
    Matsumura, Hiroya
    Okamura, Sho
    Nitta, Kazuhiro
    Uchida, Mio
    Sakura, Takuo
    Yamazato, Ryo
    Suenari, Kazuyoshi
    Watari, Yuichiro
    Fukuda, Yukihiro
    Hirao, Hidekazu
    Okamoto, Mitsunori
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (12) : A1606 - A1606